A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

NCT00048152 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

539

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: Corticosteroids
DRUG: Neoral
DRUG: Neoral
DRUG: Zenapax
DRUG: mycophenolate mofetil [CellCept]

Sponsor

Hoffmann-La Roche